FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma

Blood

Volumn 108, Issue 8, 2006, Pages 2720-2725

  Dong, Hwan Kim ^a   Hee, Du Jung ^b   Jong, Gwang Kim ^b   Lee, Je Jung ^b   Yang, Deok Hwan ^b   Yeon, Hee Park ^b   Young, Rok Do ^b   Ho, Jin Shin ^b   Min, Kyoung Kim ^b   Myung, Soo Hyun ^b   Sang, Kyun Sohn ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G; PHENYLALANINE; PREDNISONE; PROTEIN FCGR3A; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; DNA; FC RECEPTOR; FCGR2A PROTEIN, HUMAN; FCGR3A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLELE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CELL SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; EFFECTOR CELL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETICS; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DNA, NEOPLASM; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDNISONE; RECEPTORS, IGG; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 33750618232     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-01-009480     Document Type: Article

References (20)

1. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117-4126.
2. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758.
3. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279-4284.
4. Ansell SM, Witzig TE, Kurtin PJ, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002;99:67-74.
5. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635-2642.
6. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
7. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940-3947.
8. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23:474-481.
9. Ernst LK, Metes D, Herberman RB, Morel PA. Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells. J Mol Med. 2002;80:248-257.
10. van Sorge NM, van der Pol WL, van de Winkel JG. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens. 2003;61:189-202.
11. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64:4664-4669.
12. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100:1059-1070.
13. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591-6604.
14. Lin TS, Flinn IW, Modali R, et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005;105:289-291.
15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
16. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002;87:33-43.
17. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101:949-954.
18. van der Pol W, van de Winkel JG. IgG receptor polymorphisms: risk factors for disease. Immunogenetics. 1998;48:222-232.
19. Hatjiharissi E, Santo DD, Xu L, et al. Individuals Expressing FcγIIIA-158 V/V and V/F show increased NK cell surface expression of FcγRIIIA (CD16), rituximab binding, and demonstrate higher levels of ADCC activity in response to rituximab [abstract]. Blood. 2005;106:776a.
20. Wang J, Feng J, Zhang L, et al. Distribution of variant genotypes of Fc gamma receptor IIIa in healthy Chinese population of Zhengzhou city. J Huazhong Univ Sci Technolog Med Sci. 2004;23:239-241.